MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma

• Status: Unknown status
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R followed by autologous stem cells transplantation in newly-diagnosed primary central nervous system lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jun Zhu
• Treatments: Carmustine; Methotrexate; Rituximab; Temozolomide; Thiotepa

Criteria

Inclusion Criteria:

• primary central nervous system diffuse large B-cell lymphoma histologically confirmed by brain biopsy

• ECOG 0-2

• Absence of systemic disease as evaluated by chest-abdomen-pelvis CT scan

• Leucocytes>3.500/mm3, platelets>130.000/mm3, Bilirubin < 2 mg, transaminases < 2.5 N), creatinine < 150 μM/l, creatinine clearance > 50 ml/min/1.73m2

• Age 18-65 years

• Negative HIV test

• Signature of informed consent

Exclusion Criteria:

• prior chemotherapy for primary central nervous system lymphoma

• presence of another cancer (excepting basal cell carcinoma of the skin and cervical carcinoma in situ )

• systemic lymphoma (outside the CNS)

• Isolated ocular lymphoma

• Immunosuppressed patients (HIV , use of immunosuppressors)

• Other uncontrolled or progressive disease compromising shot-term survival

• Severe renal or hepatic disease

• Patients not legally covered by the French Social Security

• Inability to swallow the medication